Icon Advisers Inc. Co. Acquires 250 Shares of Celgene Co. (CELG)

Share on StockTwits

Icon Advisers Inc. Co. grew its holdings in Celgene Co. (NASDAQ:CELG) by 0.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 162,431 shares of the biopharmaceutical company’s stock after buying an additional 250 shares during the period. Celgene accounts for about 1.1% of Icon Advisers Inc. Co.’s holdings, making the stock its 25th biggest holding. Icon Advisers Inc. Co.’s holdings in Celgene were worth $10,410,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CELG. HL Financial Services LLC increased its position in Celgene by 20.5% during the third quarter. HL Financial Services LLC now owns 4,213 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 717 shares during the last quarter. FMR LLC increased its position in Celgene by 26.0% during the third quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after purchasing an additional 2,119,257 shares during the last quarter. ING Groep NV increased its position in Celgene by 116.3% during the third quarter. ING Groep NV now owns 203,229 shares of the biopharmaceutical company’s stock worth $18,187,000 after purchasing an additional 109,292 shares during the last quarter. Morgan Stanley increased its position in Celgene by 20.4% during the third quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock worth $289,620,000 after purchasing an additional 549,404 shares during the last quarter. Finally, IFM Investors Pty Ltd increased its position in Celgene by 12.3% during the third quarter. IFM Investors Pty Ltd now owns 38,302 shares of the biopharmaceutical company’s stock worth $3,428,000 after purchasing an additional 4,193 shares during the last quarter. Institutional investors and hedge funds own 75.15% of the company’s stock.

NASDAQ CELG opened at $87.91 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. Celgene Co. has a one year low of $58.59 and a one year high of $97.43. The company has a market capitalization of $61.63 billion, a PE ratio of 11.55, a price-to-earnings-growth ratio of 0.41 and a beta of 1.72.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 125.35%. The company had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. During the same quarter last year, the company earned $2.00 earnings per share. Equities research analysts anticipate that Celgene Co. will post 10.01 earnings per share for the current year.

Several research analysts have weighed in on CELG shares. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, October 25th. Mizuho set a $117.00 target price on shares of Celgene and gave the stock a “buy” rating in a research note on Tuesday, October 30th. UBS Group set a $94.00 target price on shares of Celgene and gave the stock a “buy” rating in a research note on Saturday, October 27th. reaffirmed a “buy” rating on shares of Celgene in a research note on Monday, December 3rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 target price on shares of Celgene in a research note on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $109.29.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://zolmax.com/investing/icon-advisers-inc-co-acquires-250-shares-of-celgene-co-celg/2891617.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Inter Pipeline  Price Target Lowered to C$25.00 at Royal Bank of Canada
Inter Pipeline Price Target Lowered to C$25.00 at Royal Bank of Canada
Kingfisher plc  Insider Acquires £149.50 in Stock
Kingfisher plc Insider Acquires £149.50 in Stock
Air Canada  PT Raised to C$45.00
Air Canada PT Raised to C$45.00
Draper Esprit PLC  Insider Acquires £15,000 in Stock
Draper Esprit PLC Insider Acquires £15,000 in Stock
Royal Bank of Canada Increases Fortis  Price Target to C$53.00
Royal Bank of Canada Increases Fortis Price Target to C$53.00
KeyCorp Weighs in on Brixmor Property Group Inc’s Q1 2019 Earnings
KeyCorp Weighs in on Brixmor Property Group Inc’s Q1 2019 Earnings


Leave a Reply

 
© 2006-2019 Zolmax.